COMPANY INFO
DeepCure, founded in 2018 by Joseph Jacobson, Kfir Schreiber, and Thrasyvoulos Karydis, is a private drug discovery company with approximately 49 employees headquartered in Boston, MA. The company develops a drug discovery platform that combines deep learning algorithms, cloud computing, and a proprietary chemistry database to accelerate the creation of novel small molecule therapies for immune diseases, aiming to improve pre-clinical drug development and deliver better treatments for patients. Their website is deepcure.com and they operate primarily in the drug discovery industry. (PitchBook, Tracxn)
DeepCure is a Boston-based drug discovery company leveraging advanced deep learning, cloud computing, and proprietary chemistry databases to accelerate the creation of novel small molecule therapies for immune diseases. Since its founding in 2018, DeepCure has become a leader in AI-driven approaches to drug development, aiming to improve pre-clinical drug discovery and deliver better treatment outcomes for patients.
DeepCure's executive team is a blend of technology pioneers, academic leaders, and industry veterans. The company’s management team brings together expertise from artificial intelligence, medicinal chemistry, molecular genetics, and pharmaceutical development. With backgrounds in world-renowned research institutions and biotech startups, DeepCure's executives are committed to scientific innovation, operational excellence, and strategic growth in the highly competitive field of drug discovery.
As CEO & Co-Founder, Kfir Schreiber leads DeepCure's strategic vision and operational execution, with a focus on driving the company's pioneering work in AI-driven drug discovery. Under his stewardship, DeepCure has accelerated the pace of therapy development, secured substantial venture funding, and established itself as a trusted innovator in the biotech sector.
Kfir Schreiber holds a degree from the MIT Media Lab and was the inaugural recipient of the Minsky Fellowship for outstanding AI researchers. Before co-founding DeepCure, he served as a pilot and major in the Israeli Air Force, where he gained significant leadership experience and developed a disciplined, mission-driven approach to building technology startups.
Joseph Jacobson, Co-Founder and MIT Media Lab Associate Professor, provides the scientific foundation and innovation engine for DeepCure. He has authored more than 70 peer-reviewed papers and is listed on 103 U.S. patents, strengthening DeepCure's portfolio and guiding its intellectual property strategy.
A veteran entrepreneur and academic recognized for impactful scientific discoveries, Joseph Jacobson co-founded multiple companies such as E-Ink, Gen9, Kovio, and IgC Bio. He is a member of the USPTO Inventors Hall of Fame, underscoring his extensive background in research and technology commercialization within the therapeutics sector.
As CTO & Co-Founder, Thrasyvoulos Karydis spearheads DeepCure’s technology and software development, advancing the company's deep learning and biopharma collaborations. He has led mission-critical hardware and software projects that serve as the backbone for DeepCure’s AI-based drug discovery platform.
Karydis is a former MIT and UMass Boston instructor and a graduate of the MIT Media Lab, with specialized expertise in deep learning, computational science, and biotechnology. His leadership encompasses both academia and the biotech industry, providing DeepCure with a robust technical edge.
Luca Rastelli, Chief Scientific Officer, is responsible for all scientific research and development initiatives at DeepCure. With experience leading development projects such as Tepmetko and Bavencio, he ensures innovative drug development and sets the company's scientific priorities.
Rastelli earned a Ph.D. in Molecular Biology from the University of Geneva and is an inventor on 10 patents. He has received the American Brain Tumor Association’s Translational grant, reflecting 25+ years of significant contributions to preclinical and clinical drug development.
Han Lim, Chief Business Officer, leads strategy and partnerships at DeepCure, tapping into his track record at the intersection of molecular genetics, business development, and AI-driven biotech. Previously CBO at Atomwise, he has played a pivotal role in scaling businesses and forging key industry collaborations.
Lim holds a medical degree, a Ph.D. in pediatric molecular genetics, and completed postdoctoral work in physics. He brings academic, medical, and industry experience—including tenure track research at UC Berkeley—to support DeepCure’s commercial strategy and growth ambitions.
Derrick Miyao leads DeepCure's Molecular Foundry, where he has pioneered robotic synthesis and created systems generating more than 1 million compounds. His work has been instrumental in making DeepCure’s drug discovery process faster, more scalable, and highly innovative.
Miyao previously served as Head of Automation at Neurocrine Biosciences. As a pioneer in biotech robotics and automation, he brings a wealth of experience in developing and implementing high-throughput systems for compound generation.
Derek Miller directs platform research at DeepCure, where he focuses on integrating machine learning into healthcare, genomics, and AI-enabled drug discovery. His team drives platform innovation, giving DeepCure a cutting-edge in computational drug development.
With educational credentials in telecommunications and computer science, Miller brings strong leadership in machine learning, particularly in developing healthcare and genomics solutions that fuel DeepCure’s technological advancements.
Georg Duenstl leads DeepCure’s drug discovery group, integrating computational chemistry, structural biology, and AI to design novel therapeutics. He is dedicated to advancing compounds that address unmet medical needs and furthering DeepCure's reputation as a medical innovator.
Duenstl offers over 16 years of experience, including roles as Associate Research Fellow and Chief Scientist at LEO Pharma. He holds a Ph.D. in biochemical pharmacology and executive education from the Wharton School and MIT Sloan, blending scientific depth with business acumen.
Steven Ferrara oversees medicinal chemistry at DeepCure, guiding the design and synthesis of new drug candidates. He is central to the development and progression of DeepCure’s AI-driven drug discovery pipeline.
Ferrara holds a Ph.D. in Synthetic Organic Chemistry from the University of Oxford and completed research at the Broad Institute of MIT and Harvard. He has been with DeepCure since 2021 and brings strong academic and industry research credentials.
Ayelet Wagner Azran oversees people operations for DeepCure, nurturing a culture of leadership, collaboration, and employee development. She enables organizational growth through strategic talent management and operational best practices.
Ayelet has a robust background in strategic HR and operations roles at technology firms. She holds a bachelor’s in psychology from The Open University of Israel and has studied leadership and change management at NYU, supporting DeepCure’s people-driven mission.
The DeepCure leadership team features accomplished scientists, proven technologists, and experienced business strategists. Their multidisciplinary backgrounds empower DeepCure’s ambitious mission to transform drug discovery through AI and automation. The management structure reflects a strong commitment to innovation, operational discipline, and global collaboration, with founders and executives working cohesively across scientific, technical, and commercial domains.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the DeepCure leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.